# DREAMM 7 (NCT04246047)

> Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04246047
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: GlaxoSmithKline
- Conditions: Multiple Myeloma
- Interventions: Belantamab mafodotin; Daratumumab; Bortezomib; Dexamethasone
- Enrollment: 494
- Primary outcome: Progression-free Survival (PFS)

## Commentary we found

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=dreamm-7-nct04246047